At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 100 enrolled
Drug / intervention
glecaprevir/pibrentasvirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)
In Brief
A Phase 3 clinical trial evaluating glecaprevir/pibrentasvir for Chronic Hepatitis C and 2 related conditions. Completed, enrolled 100 participants.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C virus (HCV) infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, HCV, Hepatitis C Virus
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartApr 2016
Primary CompletionApr 2017
Study CompletionJun 2017
TodayJul 2026
First PostedFeb 26, 2016
Enrollment StartApr 22, 2016
Primary CompletionApr 13, 2017
Study CompletionJun 29, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.3 years ago
Interventions
glecaprevir/pibrentasvirdrug
Tablet; glecaprevir coformulated with pibrentasvir